Chimerix (NASDAQ: CMRX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Chimerix Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Chimerix Company Info
Chimerix Inc is a biopharmaceutical company that develops and commercializes oral antivirals. It has two compounds in clinical development: CMX001 and CMX157.
News & Analysis
Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.
Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program.
A new acquisition could be quite the shot in the arm for the company.
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
This once-promising clinical-stage company is trying to prove that it's not dead yet, but investors remain skeptical.
Analysts and investors continue to warm up to the company's shares after their December implosion.
Shares are recovering today from their massive sell-off, but the company's near-term future remains a mystery.
Here's why a brand management company, a marine shipper, and a biopharmaceutical were the worst-performing small company stocks in 2015.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
CMRX earnings call for the period ending June 30, 2022.
CMRX earnings call for the period ending March 31, 2022.
CMRX earnings call for the period ending December 31, 2021.
CMRX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.